Recurrent Vulvovaginal Candidiasis (RVVC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Recurrent vulvovaginal candidiasis (RVVC) is characterized by experiencing four or more confirmed episodes of vulvovaginal candidiasis within a year, and it presents a significant challenge in effectively managing this infection. It typically results from a relapse caused by the same persistent strains of C. albicans rather than a new infection caused by different strains. This condition is more likely to develop in environments with elevated estrogen levels and often affects pregnant women. Recurrent thrush is relatively uncommon, affecting approximately 5-8% of women of reproductive age. Yet, it can profoundly impact women's quality of life, leading to symptoms like vulvar itching, soreness, painful urination, painful intercourse, and the characteristic "cottage cheese-like" vaginal discharge. Primary RVVC is considered idiopathic, as its underlying predisposing factors are unknown. It occurs in otherwise healthy, immunocompetent women, most of whom do not have identifiable triggers or causative factors. On the other hand, when frequent episodes of acute VVC are linked to predisposing factors such as hormone replacement therapy or diabetes mellitus, it is referred to as secondary RVVC. In June 2021, the FDA (Food and Drug Administration) approved a novel oral glucan synthase inhibitor called ibrexafungerp for treating recurrent vulvovaginal candidiasis.

·       VVC is the most common candidal infection in humans, affecting around 75% of women at least once during their lifetime. Furthermore, recurrent VVC impacts nearly 8% of women worldwide.

 

Thelansis’s “Recurrent Vulvovaginal Candidiasis (RVVC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Vulvovaginal Candidiasis (RVVC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Recurrent Vulvovaginal Candidiasis (RVVC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Recurrent Vulvovaginal Candidiasis (RVVC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Recurrent Vulvovaginal Candidiasis (RVVC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Recurrent Vulvovaginal Candidiasis (RVVC), Recurrent Vulvovaginal Candidiasis (RVVC) market outlook, Recurrent Vulvovaginal Candidiasis (RVVC) competitive landscape, Recurrent Vulvovaginal Candidiasis (RVVC) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)